c-Kit Receptors as a Therapeutic Target in Cancer: Current Insights

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• c-Kit, a type III receptor tyrosine kinase (RTK), regulates critical biological processes like cell survival and apoptosis.
• Aberrations in c-KIT, including overexpression and mutations, are linked to the development of numerous cancers such as gastrointestinal stromal tumors and acute myeloid leukemia.
• The critical role of c-KIT in cancer pathogenesis positions it as a significant molecular target for therapeutic intervention.

Purpose of the Study:

• To review the literature on the role of c-KIT mutations in various cancers.
• To explore the potential of tyrosine kinase inhibitors (TKIs) in managing cancers with c-KIT aberrations.
• To provide insights into c-KIT as a therapeutic target for personalized cancer treatment.

Main Methods:

• Literature review of studies investigating c-KIT mutations and their role in cancer.
• Analysis of research on the efficacy of tyrosine kinase inhibitors (TKIs) in treating c-KIT-driven malignancies.
• Synthesis of findings to evaluate c-KIT as a molecular target.

Main Results:

• c-KIT mutations are implicated in the pathogenesis of diverse cancers, including gastrointestinal stromal tumors, mastocytosis, acute myeloid leukemia, breast, thyroid, and colorectal cancer.
• Tyrosine kinase inhibitors (TKIs) represent a promising therapeutic strategy for cancers harboring c-KIT aberrations.
• The effectiveness of TKIs is dependent on the specific type of c-KIT mutation present.

Conclusions:

• c-KIT plays a significant role in various cancer types, making it a viable molecular target.
• Personalized therapy targeting c-KIT requires accurate detection of the specific underlying mutation.
• TKIs offer a potential avenue for effective cancer treatment in patients with c-KIT aberrations, underscoring the importance of targeted approaches.